Difference between revisions of "Agomelatine-venlafaxine"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugswitch | from = agomelatine | to = venlafaxine | stop = * Agomelatonine can be stopped abruptly for every dosage. | start = * No wash-out period is necessary. * Start...')
 
 
(10 intermediate revisions by 4 users not shown)
Line 2: Line 2:
 
| from = agomelatine  
 
| from = agomelatine  
 
| to = venlafaxine  
 
| to = venlafaxine  
| stop =  
+
| stop = {{StopAgomelatine}}
* Agomelatonine can be stopped abruptly for every dosage.
 
 
| start =  
 
| start =  
 +
 +
* '''Day 2:''' {{startVenla}}  Increase the dose with about 25% of the target dose every 3 days.
 +
 +
| info =
 
* No wash-out period is necessary.
 
* No wash-out period is necessary.
* Start administration of venlafaxine the next day in a normal dosage of 75 mg/day.
 
 
}}
 
}}

Latest revision as of 12:03, 14 October 2015

Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine

Switch medication from agomelatine to venlafaxine.[1] [2]

Nietinrijdenbord.png Stop agomelatine
  • Day 1: Stop agomelatine.
  • Agomelatine can be stopped abruptly for every dosage.[3]
Eenrichtingbord.png Start venlafaxine
  • Day 2: Start administration of venlafaxine in a normal dosage of 37,5 mg or 75 mg (slow release) /day. Increase the dose with about 25% of the target dose every 3 days.
Infobord.png More information
  • No wash-out period is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.